SNGX - Soligenix, Inc.

NasdaqCM - NasdaqCM Delayed Price. Currency in USD
0.7239
+0.0039 (+0.54%)
As of 2:34PM EDT. Market open.
Stock chart is not supported by your current browser
Previous Close0.7200
Open0.7000
Bid0.7202 x 900
Ask0.7300 x 1000
Day's Range0.7000 - 0.7300
52 Week Range0.6500 - 2.2000
Volume18,497
Avg. Volume104,125
Market Cap13.36M
Beta (3Y Monthly)1.92
PE Ratio (TTM)N/A
EPS (TTM)N/A
Earnings DateN/A
Forward Dividend & YieldN/A (N/A)
Ex-Dividend DateN/A
1y Target EstN/A
Trade prices are not sourced from all markets
  • Zacks Small Cap Research28 days ago

    SNGX: Interim Analysis for SGX942 Phase 3 Trial Expected in Sep. 2019…

    On April 18, 2019, Soligenix, Inc. (SNGX) announced that it has reached the enrollment target for the Phase 3 clinical trial of SGX942 (dusquetide) to support the planned interim efficacy analysis by the independent Data Monitoring Committee (DMC). The Phase 3 DOM-INNATE (Dusquetide treatment in Oral Mucositis – by modulating INNATE immunity) clinical trial is evaluating SGX942 for the treatment of sever oral mucositis (OM) in patients with squamous cell carcinoma of the oral cavity and oropharynx undergoing chemoradiation therapy.

  • Zacks Small Cap Research2 months ago

    SNGX: Enrollment Target Reached for Interim Analysis of SGX942 Phase 3 Trial…

    On April 18, 2019, Soligenix, Inc. (SNGX) announced that it has reached the enrollment target for the Phase 3 clinical trial of SGX942 (dusquetide) to support the planned interim efficacy analysis by the independent Data Monitoring Committee (DMC). The Phase 3 DOM-INNATE (Dusquetide treatment in Oral Mucositis – by modulating INNATE immunity) clinical trial is evaluating SGX942 for the treatment of sever oral mucositis (OM) in patients with squamous cell carcinoma of the oral cavity and oropharynx undergoing chemoradiation therapy.

  • Zacks Small Cap Research3 months ago

    SNGX: Interim Analysis of SGX942 in Oral Mucositis in Third Quarter of 2019…

    Soligenix, Inc. (SNGX) is currently conducting the randomized, multinational, double blind, placebo controlled Phase 3 DOM-INNATE (Dusquetide treatment in Oral Mucositis – by modulating INNATE immunity) clinical trial, which is evaluating SGX942 (dusquetide) for the treatment of severe oral mucositis (OM) in patients with squamous cell carcinoma of the oral cavity and oropharynx undergoing chemoradiation therapy. Important secondary endpoints that are being evaluated include tumor progression and overall survival at 12 months.

  • Zacks Small Cap Research4 months ago

    SNGX: Innate Defense Regulators Offer New Approach to Treating Infections

    Soligenix, Inc. (SNGX) recently published a review of the potential clinical applications for innate defense regulators (IDRs), including the company’s lead IDR asset SGX942. IDRs modulate the innate immune response, which is composed of both physical barriers (e.g., skin, mucosal surfaces, etc.) as well as specialized myeloid and lymphoid sensor and effector cells (Gasteiger et al., 2017). IDRs exert their effects through binding of p62 (sequestosome-1), which is involved in a number of different innate immune signaling networks (Yu et al., 2009).

  • Benzinga6 months ago

    The Daily Biotech Pulse: Management Change At Merck, Jazz Buyback, Arrowhead Earnings

    Here's a roundup of top developments in the biotech space over the last 24 hours. Scaling The Peak (Biotech stocks hitting 52-week highs on Dec. 10) Homology Medicines Inc (NASDAQ: FIXX ) OvaScience Inc ...

  • Zacks Small Cap Research7 months ago

    SNGX: Two Phase 3 Data Readouts Over Next 12-15 Months…

    Revenues were comprised of non-dilutive government grants and contracts in support of RiVax®, SGX301, and SGX942 as well as a subaward from the Ebola collaboration with the University of Hawaii. The increase was mainly due to increased costs associated with the ongoing Phase 3 clinical trials. As of September 30, 2018, Soligenix had cash and cash equivalents of $11.7 million, due in part to a registered direct offering in July 2018 that raised net proceeds of $8.4 million.

  • Zacks Small Cap Research8 months ago

    SNGX: Transferring Coverage; Positive Feedback from Interim Analysis gives SGX301 Phase 3 Trial 90% probability of success…

    On October 15, 2018, Soligenix, Inc. (SNGX) announced a positive recommendation from the independent Data Monitoring Committee (DMC), which conducted an unblinded analysis of the company’s ongoing Phase 3 FLASH (Fluorescent Light Activated Synthetic Hypericin) trial. The trial is testing the company’s lead product, SGX301, as a treatment for cutaneous T cell lymphoma (CTCL). The DMC recommended that the company enroll an additional 40 subjects into the trial to maintain 90% statistical power for the primary endpoint.

  • Zacks Small Cap Research8 months ago

    SNGX: Q&A with Soligenix Chief Medical Officer Dr. Richard Straube Regarding the Interim Analysis for the Phase 3 Trial of SGX301

    To clear up any confusion regarding the DMC’s recommendation and what it means for the study we spoke with Dr. Richard Straube, Soligenix’s Chief Medical Officer, and asked him a few questions regarding the outcome of the interim analysis. David Bautz: Some investors may be surprised by the required addition of 40 patients to the study. Dr. Straube: First, we want to make it clear that nothing is wrong with the study and we weren’t far off with our estimated enrollment of approximately 120 patients.

  • Benzinga8 months ago

    The Week Ahead In Biotech: Conferences, Clinical Trial Results And IPOs

    As we step into the final quarter of 2018, biotech stocks have recorded double-digit gains for the year-to-date period. Will the run up continue? Stay tuned to the following events of the upcoming week. ...

  • Zacks Small Cap Research9 months ago

    SNGX: What Can We Expect from the Upcoming Interim Analysis of Phase III SGX301 for CTCL?

    Soligenix (SNGX) is a late-stage biopharmaceutical company with two Phase III candidates. While we are waiting for the interim analysis of SGX301 in the coming month, we recently interviewed Dr. Richard C. Straube, Sr. VP & Chief Medical Officer of Soligenix (SNGX) with respect to the prospect of this late stage candidate. Following are the summary of what we get from Dr. Richard Straube.

  • Zacks Small Cap Research11 months ago

    SNGX: New Financing Boosts Balance Sheet

    In early July, Soligenix (SNGX) closed an underwritten public offering of 7,766,990 shares of its common stock and warrants to purchase up to an aggregate of 3,106,796 shares of its common stock at a combined offering price of $1.03. In addition, the underwriters partially exercised the over-allotment to purchase additional warrants to purchase 466,019 shares of common stock. Gross proceeds to Soligenix from this offering were approximately $8 million.